Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07761351

A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy

The ENCOMPASS study is a post-market, multicenter, randomized controlled trial comparing two established approaches for obtaining a biopsy of small pulmonary nodules (≤2 cm): CT-guided percutaneous lung nodule biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam CT (ssRAB with CBCT).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

CT-guided percutaneous biopsy and ssRAB with CBCT are two types of lung nodule biopsy procedures routinely used in clinical practice. The study is designed to evaluate the diagnostic efficacy and safety of ssRAB with CBCT compared with CT-guided percutaneous lung nodule biopsy in adults requiring diagnostic evaluation of a pulmonary nodule. The co-primary objectives are to assess non-inferiority of diagnostic efficacy and superiority of safety.

The primary endpoints are diagnostic efficacy and the rate of peri-procedural pneumothorax (with or without intervention) associated with the assigned biopsy approach.

Eligible participants will be randomized 1:1 to either ssRAB with CBCT or CT-guided percutaneous lung nodule biopsy. If the clinical team determines that the assigned procedure is not suitable, the participant will receive the most appropriate standard of care instead. Both biopsy procedures will be performed according to routine clinical practice, and no experimental devices or procedures will be used.

Participants will be followed for up to 12 months through medical record review and routine clinical follow-up. Patient-reported quality of life and, optionally, work status will be assessed using questionnaires at multiple time points. No research-specific assessments, burdensome tests, or advanced imaging outside of standard care will be performed. A chest X-ray will be required following the biopsy procedure, consistent with routine clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is aged 18 years or older at time of consent.
  • Diagnostic nodule biopsy(s) indicated per multidisciplinary team (or equivalent).
  • Target pulmonary nodule ≤2 cm in largest diameter.
  • Patient is willing and able to give written informed consent for clinical study participation.

Exclusion criteria

  • Patient has previously undergone a biopsy procedure of the target nodule by any approach.
  • Patient was previously randomized in this study but did not undergo biopsy.
  • Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results.
  • Patient is pregnant or breastfeeding as determined by standard site practices.
  • Patient lacks the capacity to provide informed consent for themselves, or is a vulnerable patient whose ability to protect their own interests or to consent freely may be diminished, including but not limited to, patients who may be unduly influenced through dependency on the sponsor, the hospital, or the study doctor.
  • Patient is not willing to comply with study participation requirements.

Treatment and study plan

Shape-Sensing Robotic-Assisted Bronchoscopy with Cone-Beam CT (ssRAB with CBCT)

Procedure

A bronchoscopic lung nodule biopsy procedure performed using shape-sensing robotic-assisted bronchoscopy with cone-beam CT guidance as clinically indicated and according to standard clinical practice.

Other names: ssRAB, Ion endoluminal system

CT-guided percutaneous lung nodule biopsy

Procedure

A percutaneous lung nodule biopsy procedure performed under CT imaging guidance according to standard clinical practice.

Other names: Transthoracic Needle Aspiration (TTNA), Transthoracic Needle Biopsy (TTNB)

Primary outcomes

  1. Diagnostic Efficacy of the Assigned Biopsy Procedure

    Time frame: At the index procedure

    Diagnostic efficacy will be calculated as the proportion of patients who receive their assigned treatment multiplied by diagnostic yield of their assigned treatment.

  2. Peri-Procedural Pneumothorax Rate

    Time frame: From procedure to 7 days (or until subsequent intervention, whichever occurs first).

    Rate of peri-procedural pneumothorax related to the assigned index biopsy procedure, including pneumothorax identified on routine post-procedure imaging and clinically relevant pneumothorax requiring intervention or escalation of care.

Secondary outcomes

  1. Diagnostic Yield

    Time frame: At the index procedure

    Diagnostic yield of the index biopsy procedure, defined according to American Thoracic Society (ATS) and American College of Chest Physicians (ACCP) guidance

  2. Sensitivity for Malignancy

    Time frame: Through 1 year post-procedure

    Sensitivity of the index biopsy procedure for the diagnosis of malignancy, based on final diagnosis established through 1-year follow-up

  3. Negative Predictive Value

    Time frame: Through 1 year post-procedure

    Negative predictive value of the index biopsy procedure based on final diagnosis established through 1-year follow-up

  4. Diagnostic accuracy

    Time frame: Through 1 year post-procedure

    Diagnostic accuracy of the index biopsy procedure based on final diagnosis established through 1-year follow-up.

  5. Adequacy of Specimen for Molecular and/or Immunohistochemistry Testing

    Time frame: At the index procedure

    Proportion of biopsy specimens considered adequate for molecular profiling and/or immunohistochemistry (IHC) testing.

  6. Procedure-Related Adverse Events

    Time frame: Through 30 days post-procedure or until the first invasive diagnostic or therapeutic intervention, whichever occurs first

    Incidence of procedure-related adverse events.

  7. Procedure-related serious adverse events.

    Time frame: Through 30 days post-procedure or until the first invasive diagnostic or therapeutic intervention, whichever occurs first

    Incidence of procedure-related serious adverse events.

  8. All-Cause Mortality

    Time frame: Through study exit

    Incidence of all-cause mortality among study participants.

  9. Length of Stay for Procedure-Related Adverse Events

    Time frame: From the date of hospitalization for a procedure-related adverse event until hospital discharge, for events occurring up to 30 days following the index procedure

    Duration of hospitalization attributable to procedure-related adverse events

Study contacts

Contact information is provided by the study sponsor or research team.

Carine Van den Abeele

CONTACT

[email protected]

+41 21 821 2000

Martha Bean

CONTACT

[email protected]

+41 21 821 2000

Sponsors and collaborators

Lead sponsor

Intuitive Surgical

Industry

Registry information

Official study title

A Randomized Controlled Trial Evaluating Lung Nodules - COMparing Percutaneous CT-Guided Biopsy And Shape-Sensing Robotic-Assisted Bronchoscopy (ENCOMPASS)

Acronym: ENCOMPASS

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Aug 12, 2026
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.